Merck is looking to buy Millipore in a $7.2 billion deal, which includes debt, Reuters reports. The German drugmaker has offered to pay $107 per share, which includes the assumption of Millipore’s debt.
Merck will fund the acquisition with bridge loans before refinancing, through a bond issue. Millipore, a U.S. biotech tool maker, had $1.65 billion in revenue until Dec. 31, 2009.
Click here for the complete story.
